A randomised, double-blind phase II study evaluating cediranib vs cediranib and saracatinib in patients with relapsed metastatic clear cell renal cancer (COSAK).
dc.contributor.author | Powles, T | |
dc.contributor.author | Brown, J | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Jones, R | |
dc.contributor.author | Ralph, C | |
dc.contributor.author | Hawkins, Robert E | |
dc.contributor.author | Chowdhury, S | |
dc.contributor.author | Boleti, E | |
dc.contributor.author | Bhal, A | |
dc.contributor.author | Fife, K | |
dc.contributor.author | Webb, A | |
dc.contributor.author | Crabb, S | |
dc.contributor.author | Geldart, T | |
dc.contributor.author | Hill, R | |
dc.contributor.author | Dunlop, J | |
dc.contributor.author | Hall, P | |
dc.contributor.author | McLaren, D | |
dc.contributor.author | Ackerman, C | |
dc.contributor.author | Beltran, L | |
dc.contributor.author | Nathan, P | |
dc.date.accessioned | 2016-03-30T09:37:15Z | en |
dc.date.available | 2016-03-30T09:37:15Z | en |
dc.date.issued | 2016-01-22 | en |
dc.identifier.citation | A randomised, double-blind phase II study evaluating cediranib vs cediranib and saracatinib in patients with relapsed metastatic clear cell renal cancer (COSAK). 2016: Ann Oncol | en |
dc.identifier.issn | 1569-8041 | en |
dc.identifier.pmid | 26802156 | en |
dc.identifier.doi | 10.1093/annonc/mdw014 | en |
dc.identifier.uri | http://hdl.handle.net/10541/603960 | en |
dc.description.abstract | Preclinical work suggests Src proteins have a role in the development of resistance to vascular endothelial growth factor (VEGF) targeted therapy in metastatic clear cell renal cancer (mRCC). This hypothesis was tested in this trial using the SRC inhibitor saracatinib and the VEGF inhibitor cediranib. | |
dc.language | ENG | en |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMO | en |
dc.title | A randomised, double-blind phase II study evaluating cediranib vs cediranib and saracatinib in patients with relapsed metastatic clear cell renal cancer (COSAK). | en |
dc.type | Article | en |
dc.contributor.department | The Royal Free NHS Foundation Trust, London, UK Barts Cancer Institute, CRUK Experiment Cancer Medicine Centre | en |
dc.identifier.journal | Annals of Oncology | en |
html.description.abstract | Preclinical work suggests Src proteins have a role in the development of resistance to vascular endothelial growth factor (VEGF) targeted therapy in metastatic clear cell renal cancer (mRCC). This hypothesis was tested in this trial using the SRC inhibitor saracatinib and the VEGF inhibitor cediranib. |